in a haemodialysis unit were screened for nasal carriage of S. aureus. They were considered carriers if two nasal swabs taken one week apart were positive for S. aureus. All carriers, after giving their consent, were prescribed 2% calcium mupirocin ('Nasal Bactroban'). The ointment was applied to the anterior nares three times daily for the first five days and subsequently at the end of each haemodialysis session, i.e. three times weekly. The methods for sampling the nares and for the isolation, identification, minimum inhibitory concentration (MIC) determination, and phage typing of S. aureus were as previously reported.6 Repeat swabs were obtained from both anterior nares at the end of the third and the sixth month of the trial.
The patients were followed prospectively for the development of bacteraemia caused by S. aureus. When a patient presented with fever > 38"C, with or without signs of infection, three pairs of blood cultures were collected using a standard aseptic technique.
Blood culture isolates of S. aureus were considered as relevant if grown from more than two of the six culture bottles. The incidence of S. aureus bacteraemia in the total haemodialysis population, during the six months in which nasal carriers were treated with mupirocin, was compared with the incidence of S. aureus bacteraemia during a 2-year period when mupirocin prophylaxis had not been used (which had been previously prospectively assessed3). In order to allow comparison between the two study periods, the episodes of S. aureus bacteraemia that occurred within the first month of haemodialysis, excluded from the previous 2-year incidence study,6 were included in the present comparison.
Of the 106 patients in the present trial, 71 (67%) treated with mupirocin had also been assessed for bacteraemia caused by S. aureus in the previous pre-mupirocin trial. The combined costs of prophylaxis and treatment of S. aureus bacteraemia were compared for the two study periods, with and without mupirocin prophylaxis.
In the absence of mupirocin prophylaxis, the costs assessed were those of the treatment of S. aureus bacteraemia, namely the cost of hospitalization, diagnostic investigation and drug treatment. For the 6 months of mupirocin prophylaxis, the costs included, in addition, the cost of nasal cultures plus the cost of 2% calcium mupirocin ointment (which is commercially available in the UK). The costs, in US dollars, were expressed per patient-year at risk. Table I . There was no significant difference between the two patient groups concerning the age distribution and the fraction of patients with diabetes mellitus, with iron overload (defined by a serum ferritin > lmg 1-l) or with dialysis through a central venous catheter. Of the 106 patients, 43 (41%)' were nasal carriers of S. uuwus which was always sensitive to mupirocin.
These 43 nasal carriers received mupirocin nasal ointment prophylactically for a total follow-up of 16.75 patient-years: 29 patients were followed for 6 months, 8 for 224 months and 6 for less than 2 months. A total of 60 nasal cultures was taken from 31 patients 3 and 6 months after the start of the 6 months study of mupirocin prophylaxis; none of the swabs yielded S. aureus. There was only one episode of S. aureus bacteraemia recorded during the 44.1 patient-years of follow-up, an incidence of 0.0227 per patient-year at risk. The source of S. aureu~ for the single bacteraemic episode could not be identified, and a nasal culture taken at the time of bacteraemia, prior to antibiotic therapy, failed to yield S. uureus. The S. aweus isolated from the blood was sensitive to mupirocin and was of the same phage type as the strain isolated from the patient's nose prior to mupirocin use. The 2% calcium mupirocin ointment was well tolerated in all patients. In our previous study when nasal mupirocin was not used, the cost for the treatment of an episode of S. aureu~ bacteraemia ranged from $763 to $87 229 (mean= $9249; median = $3429). The mean cost per patient-year at risk for the treatment of S. aureus bacteraemia was $896. During mupirocin prophylaxis, the calculated mean cost for the treatment of S. aureus bacteraemia per patient-year at risk was $210. The cost of monitoring nasal cultures every 3 months was $32 per patient-year and the eradication of nasal staphylococcal carriage by mupirocin in c.40% of the haemodialysis population was $60 x 0.4, or $24 per patient-year. Thus, when using mupirocin prophylaxis, the average total cost was $266. This cost is only 30% of the cost of treating S. aweus bacteraemia in the period prior to using mupirocin prophylaxis.
Discussion
We previously reported the results of a double-blind, placebo-controlled trial which showed that 2% calcium mupirocin nasal ointment was effective in eradicating nasal carriage of S. aureus and in decreasing the rate of S. aureus infections in patients on maintenance haemodialysis.6 A subsequent study in the same patient population showed that some weeks or months after a single S-day course of nasal mupirocin, S. aureus tended to recolonize the nares, while staphylococcal nasal recolonization did not occur when nasal mupirocin application was continued thrice weekly, i.e. after each haemodialysis. ' Therefore, nasal mupirocin was applied 3 times per week throughout the present study, after an initial S-day-course. 
